Importance of Nanocarriers and Probiotics in the Treatment of Ulcerative Colitis

  • Amandeep Singh Assistant Professor, Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India Postal Code: 142001.
  • Kirandeep Kaur Department of Pharmaceutics, ISF College of Pharmacy, Moga-142001, Punjab, India
  • Veerpal Kaur Department of Pharmaceutics, ISF College of Pharmacy, Moga-142001, Punjab, India
  • Gurmeet Singh Department of Pharmaceutics, ISF College of Pharmacy, Moga-142001, Punjab, India
  • Uttam Kumar Mandal Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda- 151001, Punjab, India.
  • Neeraj Mishra Department of Pharmaceutics, Amity Institute of Pharmacy, Gwalior, Madhya Pradesh, India
  • Raj Kumar Narnag Department of Pharmaceutics, ISF College of Pharmacy, Moga-142001, Punjab, India

Abstract

Ulcerative colitis (UC) is an inflammatory chronic disease primarily affecting the colonic mucosa; the extent and severity of colon involvement are variable. In its most limited form, it may be restricted to the distal rectum, while in its most extended form the entire colon is involved. Ulcerative colitis is identified by mucus diarrhea, tenesmus, bowel distension, and anemia. 5-aminosalicylic acid drugs, steroids, and immunosuppressant are used for therapy of ulcerative colitis. The annual occurrence of disease in Asia, America, and Europe was estimated to be 6.3, 19.2 and 24.3 per 100,000 people-years. The main challenges in the management of the diseaseare drug-related side-effects and local targeting. To overcome these challenges probiotics and micro and Nano particulate system auspicious approaches to overcome drug-related adverse side effect and local targeting. Upon ingestion, the probiotics can result in health beneficial effects. Probiotics are mainly used as gut modulators but are also now days explored for their use in ulcerative colitis. Micro and Nano particulate drug delivery system have been achieving huge importance for targeting of the drug to colon locally at a controlled and sustained rate. The main objective of this article is to explore probiotics and micro and nano particulate approaches for the suitable targeting and overcome the drug-associated side effect.


Keywords: Inflammatory chronic disease, probiotics, micro and Nano particulate.

Downloads

Download data is not yet available.

Author Biography

Amandeep Singh, Assistant Professor, Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India Postal Code: 142001.

Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda- 151001, Punjab, India.

References

1. Kassam Z, Belga S, Roifman I, Hirota S, Jijon H, Kaplan GG, Ghosh S, Beck PL. Inflammatory bowel disease cause-specific mortality: a primer for clinicians. Inflammatory bowel diseases. 2014;20(12):2483-92.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427.
3. Larmonier CB, Shehab KW, Ghishan FK, Kiela PR. T lymphocyte dynamics in inflammatory bowel diseases: role of the microbiome. BioMed research international. 2015;2015.
4. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World journal of gastroenterology: WJG. 2014;20(1):91.
5. Friend DR. New oral delivery systems for treatment of inflammatory bowel disease. Advanced drug delivery reviews. 2005;57(2):247-65.
6. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nature reviews Gastroenterology & hepatology. 2015;12(4):205.
7. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterology & hepatology. 2010;6(5):339.
8. Molodecky NA, Soon S, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54.
9. Ungaro R, Chang HL, Cote-Daigneaut J, Mehandru S, Atreja A, Colombel JF. Statins associated with decreased risk of new onset inflammatory bowel disease. The American journal of gastroenterology. 2016;111(10):1416.
10. Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune network. 2017;17(1):25-40.
11. Weinstock JV, Elliott DE. Helminths and the IBD hygiene hypothesis. Inflammatory bowel diseases. 2008;15(1):128-33..
12. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(suppl 5):v1-6.
13. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer letters. 2014;345(2):235-41.
14. Navaneethan U, Jegadeesan R, Gutierrez NG, Venkatesh PG, Hammel JP, Shen B, Kiran RP. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. Journal of Crohn's and Colitis. 2013;7(12):e684-91.
15. McCombie AM, Mulder RT, Gearry RB. Psychotherapy for inflammatory bowel disease: a review and update. Journal of Crohn's and Colitis. 2013;7(12):935-49.
16. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. The Journal of clinical investigation. 2007;117(3):514-21.
17. Ardizzone S, Porro GB. Inflammatory bowel disease: new insights into pathogenesis and treatment. Journal of internal medicine. 2002;252(6):475-96.
18. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. The Journal of clinical investigation. 2004;113(10):1490-7.
19. Stein J, Ries J, Barrett KE. Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. American Journal of Physiology-Gastrointestinal and Liver Physiology. 1998;274(1):G203-9.
20. Meier J, Sturm A. Current treatment of ulcerative colitis. World journal of gastroenterology: WJG. 2011;17(27):3204.
21. Taylor KM, Irving PM. Optimization of conventional therapy in patients with IBD. Nature reviews Gastroenterology & hepatology. 2011;8(11):646.
22. Ardizzone S, Porro GB. Inflammatory bowel disease: new insights into pathogenesis and treatment. Journal of internal medicine. 2002;252(6):475-96.
23. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. InMayo Clinic Proceedings 2014 (Vol. 89, No. 11, pp. 1553-1563). Elsevier.
24. Abraham BP, Ahmed T, Ali T. Inflammatory bowel disease: pathophysiology and current therapeutic approaches. InGastrointestinal Pharmacology 2017 (pp. 115-146). Springer, Cham.
25. Feagan BG, MacDonald JK. Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane database of systematic reviews. 2012(10).
26. Abraham BP, Ahmed T, Ali T. Inflammatory bowel disease: pathophysiology and current therapeutic approaches. InGastrointestinal Pharmacology 2017 (pp. 115-146). Springer, Cham.
27. Probert CS, Dignass AU, Lindgren S, Oudkerk Pool M, Marteau P. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. Journal of Crohn's and Colitis. 2014;8(3):200-7.
28. Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, Moayyedi P. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. The American journal of gastroenterology. 2011;106(4):590.
29. Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. State of the art: IBD therapy and clinical trials in IBD. Inflammatory bowel diseases. 2005;11(suppl_1):S3-12.
30. Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World journal of gastroenterology: WJG. 2013;19(7):1040.
31. Abraham BP, Ahmed T, Ali T. Inflammatory bowel disease: pathophysiology and current therapeutic approaches. InGastrointestinal Pharmacology 2017 (pp. 115-146). Springer, Cham.
32. Garud S, Peppercorn MA. Ulcerative colitis: current treatment strategies and future prospects. Therapeutic advances in gastroenterology. 2009;2(2):99-108.
33. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008;57(12):1639-41.
34. Bollegala N, Brill H, Marshall JK. Resource utilization during pediatric to adult transfer of care in IBD. Journal of Crohn's and Colitis. 2013;7(2):e55-60.
35. Meier J, Sturm A. Current treatment of ulcerative colitis. World journal of gastroenterology: WJG. 2011;17(27):3204.
36. Kim KK, Pack DW. Microspheres for drug delivery. InBioMEMS and biomedical nanotechnology 2006 (pp. 19-50). Springer, Boston, MA.
37. Lee JK, Tang DH, Mollon L, Armstrong EP. Cost-effectiveness of biological agents used in ulcerative colitis. Best Practice & Research Clinical Gastroenterology. 2013;27(6):949-60.
38. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, De Villiers WJ. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine. 2005;353(23):2462-76.
39. Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Birt J, Paavola J, Lee SK, Price J, Targan SR, Abreu MT. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. The American journal of gastroenterology. 2005;100(1):75.
40. Sowmaya C, Reddy GS, Neelaboina VP. Colon specific drug delivery systems: A review on pharmaceutical approaches with current trends. Int Res J Pharm. 2012;3(7):45-57.
41. Lautenschläger C, Schmidt C, Lehr CM, Fischer D, Stallmach A. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. European Journal of Pharmaceutics and Biopharmaceutics. 2013;85(3):578-86.
42. Talaei F, Atyabi F, Azhdarzadeh M, Dinarvand R, Saadatzadeh A. Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies. European Journal of Pharmaceutical Sciences. 2013;49(4):712-22.
43. Collnot EM, Ali H, Lehr CM. Nano-and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. Journal of Controlled Release. 2012;161(2):235-46.
44. Youshia J, Lamprecht A. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases. Expert opinion on drug delivery. 2016;13(2):281-94.
45. Coppi G, Iannuccelli V, Bernabei MT, Cameroni R. Alginate microparticles for enzyme peroral administration. International journal of pharmaceutics. 2002;242(1-2):263-6.
46. Lamprecht A, Schäfer U, Lehr CM. Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. Pharmaceutical research. 2001; 18(6):788-93.
47. Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. Journal of Pharmacology and Experimental Therapeutics. 2001; 299(2):775-81.
48. Duan H, Lü S, Qin H, Gao C, Bai X, Wei Y, Wu XA, Liu M, Zhang X, Liu Z. Co-delivery of zinc and 5-aminosalicylic acid from alginate/N-succinyl-chitosan blend microspheres for synergistic therapy of colitis. International journal of pharmaceutics. 2017; 516(1-2):214-24.
49. Duan H, Lü S, Gao C, Bai X, Qin H, Wei Y, Wu XA, Liu M. Mucoadhesive microparticulates based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon. Colloids and Surfaces B: Biointerfaces. 2016; 145:510-9.
50. Mladenovska K, Cruaud O, Richomme P, Belamie E, Raicki RS, Venier-Julienne MC, Popovski E, Benoit JP, Goracinova K. 5-ASA loaded chitosan–Ca–alginate microparticles: Preparation and physicochemical characterization. International journal of pharmaceutics. 2007; 345(1-2):59-69.
51. Mura C, Nácher A, Merino V, Merino-Sanjuan M, Manconi M, Loy G, Fadda AM, Díez-Sales O. Design, characterization and in vitro evaluation of 5-aminosalicylic acid loaded N-succinyl-chitosan microparticles for colon specific delivery. Colloids and Surfaces B: Biointerfaces. 2012; 94:199-205.
52. Melero A, Draheim C, Hansen S, Giner E, Carreras JJ, Talens-Visconti R, Garrigues TM, Peris JE, Recio MC, Giner R, Lehr CM. Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. European Journal of Pharmaceutics and Biopharmaceutics. 2017; 119:361-71.
53. Guada M, Lana H, Gil AG, del Carmen Dios-Viéitez M, Blanco-Prieto MJ. Cyclosporine A lipid nanoparticles for oral administration: pharmacodynamics and safety evaluation. European Journal of Pharmaceutics and Biopharmaceutics. 2016; 101:112-8.
54. Dai W, Guo Y, Zhang H, Wang X, Zhang Q. Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A. International journal of pharmaceutics. 2015; 478(2):718-25.
55. Oosegi T, Onishi H, Machida Y. Novel preparation of enteric-coated chitosan-prednisolone conjugate microspheres and in vitro evaluation of their potential as a colonic delivery system. European journal of pharmaceutics and biopharmaceutics. 2008; 68(2):260-6.
56. Zhang H, Shahbazi MA, Mäkilä EM, da Silva TH, Reis RL, Salonen JJ, Hirvonen JT, Santos HA. Diatom silica microparticles for sustained release and permeation enhancement following oral delivery of prednisone and mesalamine. Biomaterials. 2013; 34(36):9210-9.
57. Onishi H, Oosegi T, Machida Y. Efficacy and toxicity of Eudragit-coated chitosan–succinyl-prednisolone conjugate microspheres using rats with 2, 4, 6-trinitrobenzenesulfonic acid-induced colitis. International journal of pharmaceutics. 2008; 358(1-2):296-302.
58. Crcarevska MS, Dodov MG, Goracinova K. Chitosan coated Ca–alginate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa. European Journal of Pharmaceutics and Biopharmaceutics. 2008; 68(3):565-78.
59. Krishnamachari Y, Madan P, Lin S. Development of pH-and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. International journal of pharmaceutics. 2007; 338(1-2):238-47.
60. Cerchiara T, Abruzzo A, Di Cagno M, Bigucci F, Bauer-Brandl A, Parolin C, Vitali B, Gallucci MC, Luppi B. Chitosan based micro-and nanoparticles for colon-targeted delivery of vancomycin prepared by alternative processing methods. European Journal of Pharmaceutics and Biopharmaceutics. 2015; 92:112-9.
61. Berthold A, Cremer K, Kreuter J. Collagen microparticles: carriers for glucocorticosteroids. European journal of pharmaceutics and biopharmaceutics. 1998; 45(1):23-9.
62. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004; 126(6):1620-33.
63. Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K, Skarmoutsou N, Fakiri EM. Health benefits of probiotics: a review. ISRN nutrition. 2013; 2013.
64. Figueroa-González I, Cruz-Guerrero A, Quijano G. The benefits of probiotics on human health. J Microbial Biochem Technol S. 2011;1:1948-5948.
65. Soccol CR, Vandenberghe LP, Spier MR, Medeiros AB, Yamaguishi CT, Lindner JD, Pandey A, Thomaz-Soccol V. The potential of probiotics: a review. Food Technology and Biotechnology. 2010 Dec 15;48(4):413-34.
66. Bergmann KR, Liu SX, Tian R, Kushnir A, Turner JR, Li HL, Chou PM, Weber CR, De Plaen IG. Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis. The American journal of pathology. 2013; 182(5):1595-606.
67. Odhav B, Krishna SB. Probiotics: Recent Understandings and Bio-medical Applications.
68. Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clinical nutrition. 2014; 33(5):761-7.
69. Petrova MI, Lievens E, Malik S, Imholz N, Lebeer S. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Frontiers in physiology. 2015; 6:81.
70. Anom EY, Udenigwe CC. Novel Approaches to Enhance the Functionality of Fermented Foods. Nutraceutical and Functional Food Processing Technology. 2015;269.
71. Hajela N, Ramakrishna BS, Nair GB, Abraham P, Gopalan S, Ganguly NK. Gut microbiome, gut function, and probiotics: Implications for health. Indian Journal of Gastroenterology. 2015; 34(2):93-107.
72. Surono IS, Martono PD, Kameo S, Suradji EW, Koyama H. Effect of probiotic L. plantarum IS-10506 and zinc supplementation on humoral immune response and zinc status of Indonesian pre-school children. Journal of Trace Elements in Medicine and Biology. 2014; 28(4):465-9.
73. Wen K, Tin C, Wang H, Yang X, Li G, Giri-Rachman E, Kocher J, Bui T, Clark-Deener S, Yuan L. Probiotic Lactobacillus rhamnosus GG enhanced Th1 cellular immunity but did not affect antibody responses in a human gut microbiota transplanted neonatal gnotobiotic pig model. PloS one. 2014; 9(4):e94504.
74. Kruis W, Frič P, Pokrotnieks J, Lukáš M, Fixa B, Kaščák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004; 53(11):1617-23.
75. Fábrega MJ, Rodríguez-Nogales A, Garrido-Mesa J, Algieri F, Badía J, Giménez R, Gálvez J, Baldomà L. Intestinal anti-inflammatory effects of outer membrane vesicles from Escherichia coli Nissle 1917 in DSS-experimental colitis in mice. Frontiers in microbiology. 2017; 8:1274.
76. Corrêa NB, Péret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. Journal of clinical gastroenterology. 2005; 39(5):385-9.
77. Kruis W, Frič P, Pokrotnieks J, Lukáš M, Fixa B, Kaščák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004; 53(11):1617-23.
78. Fábrega MJ, Rodríguez-Nogales A, Garrido-Mesa J, Algieri F, Badía J, Giménez R, Gálvez J, Baldomà L. Intestinal anti-inflammatory effects of outer membrane vesicles from Escherichia coli Nissle 1917 in DSS-experimental colitis in mice. Frontiers in microbiology. 2017; 8:1274.
79. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane database of systematic reviews. 2011(12).
80. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, Vitolo D, Boirivant M. Probiotic administration in patients with ileal pouch–anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflammatory bowel diseases. 2008; 14(5):662-8.
81. Zocco MA, Dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary pharmacology & therapeutics. 2006; 23(11):1567-74.
82. Lorén V, Manyé J, Fuentes MC, Cabré E, Ojanguren I, Espadaler J. Comparative effect of the I3. 1 probiotic formula in two animal models of colitis. Probiotics and antimicrobial proteins. 2017; 9(1):71-80.
83. Wang BG, Xu HB, Xu F, Zeng ZL, Wei H. Efficacy of oral Bifidobacterium bifidum ATCC 29521 on microflora and antioxidant in mice. Canadian journal of microbiology. 2015; 62(3):249-62.
84. Chauhan R, Sudhakaran Vasanthakumari A, Panwar H, Mallapa RH, Duary RK, Batish VK, Grover S. Amelioration of colitis in mouse model by exploring antioxidative potentials of an indigenous probiotic strain of Lactobacillus fermentum Lf1. BioMed research international. 2014;2014.
Statistics
45 Views | 61 Downloads
How to Cite
Singh, A., Kaur, K., Kaur, V., Singh, G., Mandal, U. K., Mishra, N., & Narnag, R. K. (2019). Importance of Nanocarriers and Probiotics in the Treatment of Ulcerative Colitis. Journal of Drug Delivery and Therapeutics, 9(6-s), 216-228. https://doi.org/10.22270/jddt.v9i6-s.3727

Most read articles by the same author(s)